Reference : Budesonide/formoterol maintenance and reliever therapy versus conventional best practice.
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/2268/4070
Budesonide/formoterol maintenance and reliever therapy versus conventional best practice.
English
Demoly, Pascal [> > > >]
Louis, Renaud mailto [Centre Hospitalier Universitaire de Liège - CHU > > Pneumologie-Allergologie >]
Soes-Petersen, Ulrik [> > > >]
Naya, Ian [> > > >]
Carlsheimer, Asa [> > > >]
Worth, Heinrich [> > > >]
Almeida, Joao [> > > >]
Sears, Malcolm R [> > > >]
2009
Respiratory medicine
103
11
1623-32
Yes
International
1532-3064
1532-3064
England
[en] Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) reduces asthma exacerbations and symptoms versus fixed-dose regimens plus short-acting beta(2)-agonists (SABA) in double-blind trials. Information is lacking regarding its effectiveness versus conventional best practice (CBP). This pooled analysis of six 6-month, randomized, open-label studies examined asthma control and exacerbation risk in asthmatics (aged> or =12 years). Patients (N=7855) symptomatic on inhaled corticosteroids (ICS) or stable/symptomatic on ICS/long-acting beta(2)-agonists (LABA) received budesonide/formoterol maintenance and reliever therapy (160/4.5microg bid and as needed) or CBP (ICS or ICS/LABA+/-other agents at an approved dose plus as-needed SABA). Overall asthma control was assessed comparing the incidence of exacerbations and levels of asthma control using the asthma control questionnaire (ACQ). Budesonide/formoterol maintenance and reliever therapy did not significantly reduce time to first severe exacerbation (primary variable) versus CBP (P=0.062). However, patients in this group experienced 15% fewer exacerbations (0.20 versus 0.24/patient/year; P=0.021) and used 27% less ICS (P<0.0001). Odds of remaining well controlled (ACQ< or =0.75) over 6 months were higher with budesonide/formoterol maintenance and reliever therapy versus CBP (45% versus 41%, odds ratio [OR] 1.29; P<0.01) while risk of remaining uncontrolled decreased (25% versus 29%, OR 0.81; P<0.01). Budesonide/formoterol maintenance and reliever therapy improves key aspects of asthma control versus physicians' choice of CBP.
http://hdl.handle.net/2268/4070
10.1016/j.rmed.2009.07.018
http://www.sciencedirect.com/science?_ob=PublicationURL&_tockey=%23TOC%237138%232009%23998969988%231528250%23FLA%23&_cdi=7138&_pubType=J&_auth=y&_acct=C000026659&_version=1&_urlVersion=0&_userid=532038&md5=e261e49982e1d6981844b2c72153778f

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Budesonide_formoterol maintenance and reliever therapy versus conventional best practice_Demoly_09_RespirMed.pdfPublisher postprint567.09 kBRequest copy
Open access
Budesonide_formoterol maintenance and reliever therapy versus conventional best practice_Demoly_09_RespirMed.pdfAuthor postprint567.09 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.